NEW YORK / Aug 17, 2023 / Business Wire / Oscar Health, Inc. (“Oscar”) (NYSE: OSCR), the first health insurance company built on a full stack technology platform, today announced that Chief Financial Officer, Scott Blackley, is scheduled to present at the 2023 Wells Fargo Healthcare Conference on Wednesday, September 6, 2023 at approximately 1:30 p.m. ET. In addition, Chief Executive Officer, Mark Bertolini, is scheduled to present at the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11, 2023 at approximately 8:00 a.m. ET.
All interested parties are invited to listen to a live webcast of these presentations by visiting www.ir.hioscar.com and selecting the “Events & Presentations” link. Following each presentation, a webcast replay will be available on Oscar’s investor relations website for a period of 90 days.
About Oscar Health
Oscar Health, Inc. (“Oscar”) is the first health insurance company built around a full stack technology platform and a relentless focus on serving its members. At Oscar, our mission is to make a healthier life accessible and affordable for all. Headquartered in New York City, Oscar has been challenging the health care system's status quo since our founding in 2012. The company’s member-first philosophy and innovative approach to care has earned us the trust of nearly one million members, as of June 30, 2023. We offer Individual & Family, Small Group and Medicare Advantage plans, and +Oscar, our full stack technology platform, to others within the provider and payor space. Our vision is to refactor health care to make good care cost less. Refactor is a term used in software engineering that means to improve the design, structure, and implementation of the software, while preserving its functionality. At Oscar, we take this definition a step further. We improve our members’ experience by building trust through deep engagement, personalized guidance, and rapid iteration.
Last Trade: | US$14.80 |
Daily Change: | -0.95 -6.03 |
Daily Volume: | 13,704,020 |
Market Cap: | US$3.130B |
February 04, 2025 November 07, 2024 August 22, 2024 August 07, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load